Formycon AG
http://www.formycon.com/
Already a Biomedtracker subscriber?
You have access to the full company record through your subscription
Want to become a subscriber?
Subscribers get more company details, updates, company financials and company products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Formycon AG
Keeping Track: US FDA Clears Santen’s Omlonti, Fennec’s Pedmark; Lilly’s Retevmo Adds Tumor-Agnostic Claim
The latest drug approval news and highlights from the Pink Sheet’s US FDA Performance Tracker
Formycon Reveals Keytruda Biosimilar In The Works
Formycon has revealed that pembrolizumab is one of its six biosimilars in development. The blockbuster reference biologic Keytruda brought in $17.2bn for Merck & Co. in 2021.
Bioeq’s Lucentis Biosimilar Is Given EU Go-Ahead
Bioeq’s Ranivisio ranibizumab biosimilar has gained European Commission authorization for all innovator indications including wet AMD, the leading cause of blindness among over-65s.
Formycon Reports Positive Phase III Data On Ustekinumab
Formycon has reported positive preliminary efficacy and safety data from the Phase III program for its FYB202 proposed ustekinumab biosimilar rival to Stelara.
Company Information
- Industry
- Pharmaceuticals
-
Biotechnology
- Large Molecule